GSK to Buy Nuvalent for $10.6B to Bolster Its Lung-Cancer Pipeline
GSK agreed to acquire Nuvalent for $10.6 billion ($124/share, a 40% premium) — its biggest deal to date — for two late-stage targeted lung-cancer drugs.
TL;DR — GSK agreed to acquire Nuvalent for $10.6 billion ($124/share, a 40% premium) — its biggest deal to date — to add two late-stage targeted lung-cancer drugs, zidesamtinib (ROS1) and neladalkib (ALK), with FDA decisions due later in 2026.
GSK is making its biggest bet yet on cancer. On June 9, 2026, it agreed to acquire Nuvalent for $10.6 billion.
The deal
GSK agreed to acquire Nuvalent for $10.6 billion — $124.00 per share in cash, a 40% premium to the prior close — its biggest acquisition to date and third major deal of 2026. The prize is two late-stage targeted therapies for non-small cell lung cancer: zidesamtinib (a selective ROS1 inhibitor) and neladalkib (a selective ALK inhibitor), with FDA decision dates of Sept 18 and Nov 27, 2026.
| Detail | |
|---|---|
| Deal value | $10.6B ($124/share) |
| Premium | 40% |
| Lead assets | zidesamtinib (ROS1), neladalkib (ALK) |
| FDA dates | Sep 18 & Nov 27, 2026 |
What they said
"The two lead products are potential best-in-class assets that could launch this year if approved by the FDA and offer significant new treatment options to patients." — Luke Miels, CEO, GSK
Why it matters
- Oncology firepower. GSK buys two near-market precision lung-cancer drugs.
- Two mutations, one deal. ROS1 and ALK are distinct NSCLC drivers, broadening reach.
- Big Pharma M&A continues. It positions GSK against Pfizer and Roche in targeted oncology.
FAQ
Why is GSK acquiring Nuvalent?
To strengthen its oncology pipeline. The $10.6 billion deal (announced June 9, 2026) adds two late-stage non-small cell lung-cancer drugs — zidesamtinib (a ROS1 inhibitor) and neladalkib (an ALK inhibitor) — with FDA decisions due September 18 and November 27, 2026.
How much is GSK paying, and is it a premium?
GSK is paying $10.6 billion, or $124.00 per Nuvalent share in cash — a 40% premium to the prior close and GSK’s biggest acquisition to date.
Sources
Image: “GSK headquarters, Brentford” by belemita, CC BY 3.0, via Wikimedia Commons.
← Back to all posts